The FDA Grants Fast Track Designation To Johnson & Johnson's Nipocalimaba For Systemic Lupus Erythematosus
Johnson & Johnson -0.60% Pre
Johnson & Johnson JNJ | 238.67 237.00 | -0.60% -0.70% Pre |
- Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline
- The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing
- Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage
- Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosus
